Medical Transcription Billing, Corp. (NASDAQ:MTBC) tinted gains of +2.76% (+0.09 points) to US$3.35. The volume of 0.07 Million shares climbed down over an trading activity of 425.55 Million shares. EPS ratio determined by looking at last 12 month figures is -0.71. Over the same time span, the stock marked US$5.44 as its best level and the lowest price reached was US$0.29. The corporation has a market cap of US$39.26 Million.
Medical Transcription Billing, Corp. (NASDAQ:MTBC)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 26 percent. The return on equity ratio or ROE stands at -58.1 percent while most common profitability ratio return on investment (ROI) was -22.3 percent. The company’s institutional ownership is monitored at 2.4 percent. The company’s net profit margin has achieved the current level of -23.9 percent and possesses 44.4 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is worth US$11.81 Million and has recently risen 2.75% to US$0.37. The latest exchange of 0.18 Million shares is below its average trading activity of 1.21 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$5.02 while the mean 12-month price target for the shares is US$3.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.46, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 2.2%, it carries an earnings per share ratio of -3.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.